GW Pharmaceuticals Net debt/EBITDA
What is the Net debt/EBITDA of GW Pharmaceuticals?
The Net debt/EBITDA of GW Pharmaceuticals is 34.83
What is the definition of Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA of companies in the Health Care sector on NASDAQ compared to GW Pharmaceuticals
Companies with net debt/ebitda similar to GW Pharmaceuticals
- Utz Brands has Net debt/EBITDA of 34.70
- Yuexiu Property has Net debt/EBITDA of 34.71
- GTT Communications Inc has Net debt/EBITDA of 34.74
- Sotherly Hotels Inc has Net debt/EBITDA of 34.76
- eCargo has Net debt/EBITDA of 34.81
- American Campus Communities has Net debt/EBITDA of 34.81
- GW Pharmaceuticals has Net debt/EBITDA of 34.83
- Trustmark has Net debt/EBITDA of 34.85
- Midwest Emissions has Net debt/EBITDA of 34.86
- Armada Hoffler Properties has Net debt/EBITDA of 34.87
- China Taiping Insurance has Net debt/EBITDA of 34.91
- Eastman Kodak Co has Net debt/EBITDA of 34.91
- Lifetime Brands has Net debt/EBITDA of 34.94